Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Docetaxel

FDA-approved product (injectable, injection), marketed as Beizray, Docefrez, Docetaxel and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Docetaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Gastric adenocarcinoma
  • Gastric cancer
  • Gastric carcinoma
  • Gastroesophageal junction adenocarcinoma
  • Head and neck carcinoma
  • Head and neck malignant neoplasia
  • Head and neck neoplasia
  • Head and neck squamous cell carcinoma
  • Malignant tumor of neck
  • Metastatic prostate cancer
  • Neoplasm
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
FDA pharmacologic class
Microtubule Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Docetaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Docetaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

    NCT06392841 · start 2025-10

    Registered record
    Registry ID
    NCT06392841
    Conditions
    Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Deleterious HRR Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CHEK2 Gene Mutation; FANCA Gene Mutation; PALB2 Gene Mutation; RAD51B Gene Mutation; RAD54L Gene Mutation
    Interventions
    Androgen Deprivation Therapy (ADT); Niraparib/Abiraterone Acetate DAT; Abiraterone Acetate; Prednisone; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2025-10
    Completion
    2029-01-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Hormone-sensitive Prostate Cancer (mHSPC); Deleterious HRR Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation +6 more
    InterventionAndrogen Deprivation Therapy (ADT); Niraparib/Abiraterone Acetate DAT; Abiraterone Acetate; Prednisone +1 more
    PhasePhase 2
    Registry statusWithdrawn

  • Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

    NCT07139041 · start 2025-10

    Registered record
    Registry ID
    NCT07139041
    Conditions
    NSCLC (Non-small-cell Lung Cancer)
    Interventions
    Iparomlimab and tuvonralimab plus chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-10
    Completion
    2029-06
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC (Non-small-cell Lung Cancer)
    InterventionIparomlimab and tuvonralimab plus chemotherapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

    NCT07003074 · start 2025-06-23

    Registered record
    Registry ID
    NCT07003074
    Conditions
    Breast Cancer
    Interventions
    TQB2102 for Injection; Docetaxel combined + Trastuzumab +Pertuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-06-23
    Completion
    2030-07
    Enrolment
    642

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionTQB2102 for Injection; Docetaxel combined + Trastuzumab +Pertuzumab
    PhasePhase 3
    Registry statusRecruiting

  • A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

    NCT06949761 · start 2025-06

    Registered record
    Registry ID
    NCT06949761
    Conditions
    Solid Tumor
    Interventions
    QLC1101+QL1203; QLC1101+QL2107; QLC1101+QL1706; QLC1101+docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-06
    Completion
    2027-06
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionQLC1101+QL1203; QLC1101+QL2107; QLC1101+QL1706; QLC1101+docetaxel
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

    NCT05910827 · start 2024-02-05

    Registered record
    Registry ID
    NCT05910827
    Conditions
    Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Esophageal Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma; Nasopharyngeal Cancinoma (NPC); Squamous Cell Carcinoma
    Interventions
    HMBD-001; Docetaxel; Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-02-05
    Completion
    2027-12
    Enrolment
    398

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced or Metastatic Squamous Non-Small Cell Lung Cancer; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Esophageal Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma +3 more
    InterventionHMBD-001; Docetaxel; Cetuximab
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors

    NCT06186726 · start 2024-01-26

    Registered record
    Registry ID
    NCT06186726
    Conditions
    Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
    Interventions
    carbon ion radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-26
    Completion
    2029-12-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
    Interventioncarbon ion radiotherapy
    PhasePhase 2
    Registry statusRecruiting

  • Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

    NCT05713838 · start 2023-08-28

    Registered record
    Registry ID
    NCT05713838
    Conditions
    Esophagus Adenocarcinoma
    Interventions
    Durvalumab; FLOT; mFOLFOX-6; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-08-28
    Completion
    2028-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophagus Adenocarcinoma
    InterventionDurvalumab; FLOT; mFOLFOX-6; Radiotherapy
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

    NCT05867420 · start 2023-08-02

    Registered record
    Registry ID
    NCT05867420
    Conditions
    Advanced Solid Tumors
    Interventions
    ASKG915; Paclitaxel + Bevacizumab; Fruquintinib; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-08-02
    Completion
    2028-06-30
    Enrolment
    594

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionASKG915; Paclitaxel + Bevacizumab; Fruquintinib; Docetaxel
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

    NCT05676203 · start 2023-05-16

    Registered record
    Registry ID
    NCT05676203
    Conditions
    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Interventions
    Standard ADT (androgen deprivation therapy); Standard Darolutamide; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-05-16
    Completion
    2026-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    InterventionStandard ADT (androgen deprivation therapy); Standard Darolutamide; Docetaxel
    PhasePhase 3
    Registry statusActive not recruiting

  • Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial

    NCT05755646 · start 2023-03-10

    Registered record
    Registry ID
    NCT05755646
    Conditions
    Hand-Foot Syndrome; Breast Cancer
    Interventions
    Ice Plant Intensive Cream plus Standard Care; Standard Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-03-10
    Completion
    2024-05-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand-Foot Syndrome; Breast Cancer
    InterventionIce Plant Intensive Cream plus Standard Care; Standard Care
    PhaseNot applicable
    Registry statusCompleted

  • Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

    NCT04654403 · start 2022-01-01

    Registered record
    Registry ID
    NCT04654403
    Conditions
    Esophageal Cancer
    Interventions
    Camrelizumab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-01-01
    Completion
    2022-12-31
    Enrolment
    337

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Cancer
    InterventionCamrelizumab
    PhaseNot applicable
    Registry statusUnknown

  • Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

    NCT04784715 · start 2021-04-26

    Registered record
    Registry ID
    NCT04784715
    Conditions
    Breast Cancer; HER2-positive; Metastatic
    Interventions
    Trastuzumab deruxtecan; Placebo; Taxane; Pertuzumab; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-04-26
    Completion
    2029-12-30
    Enrolment
    1,157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; HER2-positive; Metastatic
    InterventionTrastuzumab deruxtecan; Placebo; Taxane; Pertuzumab +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Benefit Population Atlas of nICT Versus nCT for LAGC

    NCT07098104 · start 2019-11-01

    Registered record
    Registry ID
    NCT07098104
    Conditions
    Gastric Cancer
    Interventions
    Immunotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-11-01
    Completion
    2025-05-01
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    InterventionImmunotherapy
    PhaseNot recorded
    Registry statusCompleted

  • REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

    NCT03951831 · start 2019-05-16

    Registered record
    Registry ID
    NCT03951831
    Conditions
    Prostate Cancer Metastatic
    Interventions
    REGN2810; Degarelix; Leuprolide Acetate; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-05-16
    Completion
    2028-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionREGN2810; Degarelix; Leuprolide Acetate; Docetaxel
    PhasePhase 2
    Registry statusActive not recruiting

  • ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

    NCT03769506 · start 2019-05-09

    Registered record
    Registry ID
    NCT03769506
    Conditions
    Head and Neck Cancer
    Interventions
    ASP-1929 Photoimmunotherapy; Physician's Choice SOC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-05-09
    Completion
    2025-12
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    InterventionASP-1929 Photoimmunotherapy; Physician's Choice SOC
    PhasePhase 3
    Registry statusActive not recruiting